BAJAJHCARE

Bajaj Healthcare share price & financials

Price
₹312.95
Market cap
₹1.1k Cr
Sector
Healthcare
Calls analysed
1
Latest concall · Q1 FY27 · call held 21 Jul 2026

Bajaj Healthcare Limited Q1 FY27

Revenue ₹165.6 cr +11%EBITDA ₹29.6 cr EBITDA Margin 17.8% PAT ₹13.9 cr +14%

What went well

  • Revenue increased by 11.3% year-on-year to INR165.6 crores.
  • Gross margin expanded by 210 basis points to 48.3%.
  • EBITDA margin improved by 70 basis points year-on-year to 17.8%.

What to watch

  • Inventory levels increased due to strategic ordering in response to geopolitical situations, though expected to normalize.
  • API prices remain dependent on geopolitical situations and oil prices, posing a potential volatility risk.
Read the full call →

What Bajaj Healthcare Limited does

Bajaj Healthcare Limited manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, Finished Dosage Forms (tablets, capsules, powders) and nutraceuticals across facilities in Maharashtra and Gujarat. It is one of the world's major manufacturers of Chlorhexidine base and India's major manufacturer of Ascorbic Acid, and is the only private player undertaking Alkaloid (Opium Gum and Poppy Straw) extraction work for the Government of India. The company also runs a CDMO business making APIs under contract for overseas customers, a dedicated oncology division (Bajaj Oncocare), and is building out peptide synthesis (including GLP-1/Semaglutide) capability.

Segments

  • Active Pharmaceutical Ingredients (APIs)
  • Intermediates
  • Finished Dosage Forms (FDFs)
  • CDMO
  • Alkaloid Processing
  • Bajaj Oncocare
Manufacturing facilities
20 (18 API/Intermediate plants across Tarapur MH, Vadodara & Panoli GJ; 2 FDF plants at Manjusar GJ and Nashik MH)
Dedicated workforce
1,500+
API & Intermediate capacity
730 MT/month APIs + 94 MT/month Intermediates
Finished Dosage Forms capacity
100 Mn pieces/month
Alkaloid processing capacity
250 MTPA Opium Gum, 2,500 MTPA Poppy Straw (Vadodara plant)
Countries with product presence
60+
Founded 1993Headquarters Thane, Maharashtra, IndiaEmployees 1,500 (FY26 (Dec 2025)) Company website

Guidance record · Q1 FY27

what the last two calls moved 9 tracked 0 delivered 0 missed 9 open
  • Consolidated Revenue Growth open said Q1 FY27 Promised: 10% to 15% for the year 2027 Q1 FY27: Guidance of 10-15% growth for FY27 provided.

All 9 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 11.4%, net profit up 16.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue133 123 154 149 148 +11%161 +31%153 −1%166 +11%
EBITDA25 22 12 25 27 +8%31 +41%23 +92%29 +16%
Net profit9 12 11 12 11 +22%16 +33%-23 −309%14 +17%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −21.9% 1Y

₹300₹350₹400₹450₹500Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q1 FY27 — 21 Jul 2026

1Y: ₹427.55 on 10 Sept 2025 → ₹334.05. High ₹507.25 (24 Sept 2025), low ₹274.95 (18 May 2026).

How the price took the results

close before → close after

Q1 FY27
−4.4%
21 Jul

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue fell 2.2% a year over 3 years, FY23 to FY26. Operating margin held at 17.3%.

Year endingFY23FY24FY25FY26
Revenue₹654 Cr₹474 Cr₹542 Cr₹611 Cr
Operating profit₹112 Cr₹77 Cr₹83 Cr₹106 Cr
Operating margin17.1%16.2%15.3%17.3%
Interest₹19 Cr₹30 Cr₹28 Cr₹23 Cr
Depreciation₹20 Cr₹27 Cr₹29 Cr₹28 Cr
Net profit₹43 Cr₹-83 Cr₹39 Cr₹16 Cr
Net margin6.6%-17.5%7.2%2.6%
Cash from operations₹-22 Cr₹92 Cr₹22 Cr₹58 Cr
Free cash flow₹-115 Cr₹73 Cr₹10 Cr₹18 Cr
ROCE14.0%8.0%11.0%11.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹16 Cr₹17 Cr
Reserves₹245 Cr₹315 Cr₹354 Cr₹265 Cr₹471 Cr₹516 Cr
Borrowings₹181 Cr₹257 Cr₹415 Cr₹333 Cr₹238 Cr₹249 Cr
Other liabilities₹86 Cr₹136 Cr₹115 Cr₹154 Cr₹114 Cr₹141 Cr
Total liabilities₹526 Cr₹721 Cr₹898 Cr₹765 Cr₹839 Cr₹923 Cr
Fixed assets₹208 Cr₹270 Cr₹366 Cr₹253 Cr₹251 Cr₹248 Cr
Capital work in progress₹57 Cr₹52 Cr₹22 Cr₹7 Cr₹6 Cr₹8 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹260 Cr₹399 Cr₹510 Cr₹506 Cr₹582 Cr₹667 Cr
Total assets₹526 Cr₹721 Cr₹898 Cr₹765 Cr₹839 Cr₹923 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs trimmed −1.24 pp while FIIs added +1.10 pp. The shareholder count grew 15% to 41,310.

Promoters
58.6%
FIIs
2.2%
DIIs
1.9%
Public
37.3%

Since Jun 2025

  • DIIs −1.24 pp
  • FIIs +1.10 pp
  • Public +0.74 pp

How it drifted, 12 quarters

Over this window promoters fell from 67.7% to 58.6% — −9.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 67.7%, FIIs 0.7%, DIIs 0.4%, Public 31.2%.Dec '23: Promoters 67.7%, FIIs 0.7%, DIIs 0.5%, Public 31.1%.Mar '24: Promoters 67.7%, FIIs 0.5%, DIIs 0.4%, Public 31.3%.Jun '24: Promoters 67.7%, Public 32.3%.Sep '24: Promoters 59.2%, FIIs 1.1%, DIIs 2.0%, Public 37.8%.Dec '24: Promoters 59.2%, FIIs 1.0%, DIIs 2.4%, Public 37.5%.Mar '25: Promoters 59.2%, FIIs 1.1%, DIIs 2.5%, Public 37.3%.Jun '25: Promoters 59.2%, FIIs 1.1%, DIIs 3.2%, Public 36.6%.Sep '25: Promoters 59.2%, FIIs 1.1%, DIIs 3.0%, Public 36.7%.Dec '25: Promoters 59.2%, FIIs 1.2%, DIIs 3.0%, Public 36.7%.Mar '26: Promoters 58.3%, FIIs 2.0%, DIIs 2.9%, Public 36.8%.Jun '26: Promoters 58.6%, FIIs 2.2%, DIIs 1.9%, Public 37.3%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Bajaj Healthcare Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Sajankumar Rameshwarlal Bajaj 36.62%unchanged
Anil Champalal Jain 6.05%+0.30 pp
Namrata Bajaj 4.85%unchanged
Nihita Bajaj Kumar 4.81%unchanged
Babita Sajankumar Bajaj 4.47%unchanged
Deepak Ramanlal Joshi 2.32%unchanged
HDFC Mutual Fund - HDFC Pharma And Healthcare Fund Mutual fund1.69%unchanged
Padma Anil Jain 0.90%unchanged
Bajaj Health And Nutritions Llp 0.71%unchanged
Bansal Pharma Limited 0.18%unchanged
Skr Bajaj Huf 0.00%unchanged
Vanaja Sundar Iyer —off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in BAJAJHCARE

Filings to Jul 2026

0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).

Held by funds
₹19 Cr
1 schemes
Biggest holder
HDFC Pharma and Healthcare Fund
₹19 Cr · 0.7% of that fund
SchemeHoldingLast month
HDFC Pharma and Healthcare Fund HDFC Mutual Fund₹19 Crheld

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Jul 2026

0 added, 0 trimmed — net 0 shares (+0.0%)

Funds are sitting on
-34%
vs est. average cost
Held by funds
₹19 Cr
1 schemes · ≈ 1.6% of the company

Shares held by these funds +1120%

Nov '24 5.69 L shares Jul '26

Learn to analyse Bajaj Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.